-
1.发明授权公开(公告)号：US11639353B2
公开(公告)日：2023-05-02
申请号：US17212210
申请日：2021-03-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Pratik Devasthale , Fang Moore , Guohua Zhao , Susan Nicole Pieniazek , Kumaravel Selvakumar , Suresh Dhanusu , Manoranjan Panda , Lawrence R. Marcin
IPC: C07D471/04 , A61K31/4375 , A61P1/16 , A61P13/12 , A61P11/00 , A61P35/00
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
2.发明申请公开(公告)号：US20210246136A1
公开(公告)日：2021-08-12
申请号：US17212210
申请日：2021-03-25
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Pratik Devasthale , Fang Moore , Guohua Zhao , Susan Nicole Pieniazek , Kumaravel Selvakumar , Suresh Dhanusu , Manoranjan Panda , Lawrence R. Marcin
IPC: C07D471/04 , A61P1/16 , A61P13/12 , A61P11/00 , A61P35/00
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
公开(公告)号：US10968219B2
公开(公告)日：2021-04-06
申请号：US16347844
申请日：2017-11-07
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Guohua Zhao , Pratik Devasthale , Xiang-Yang Ye , Kumaravel Selvakumar , Suresh Dhanusu , Palanikumar Balasubramanian , Leatte R. Guernon , Rita Civiello , Xiaojun Han , Michael Frederick Parker , Swanee E. Jacutin-Porte
IPC: C07D471/04 , C07D491/04 , C07D519/00 , A61P11/00 , A61P19/10 , A61P35/00 , A61P37/06
Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
-
4.发明申请公开(公告)号：US20140031337A1
公开(公告)日：2014-01-30
申请号：US14041665
申请日：2013-09-30
Applicant: Bristol-Myers Squibb Company
IPC: C07D487/04 , A61K31/541 , A61K31/53
CPC classification number: C07D487/04 , A61K31/53 , A61K31/541
Abstract: The present application provides compounds that are useful as MCHR1 antagonists, especially for the treatment of obesity, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein the variables are defined herein.
Abstract translation: 本申请提供了可用作MCHR1拮抗剂的化合物，特别是用于治疗肥胖症，包括根据式I的所有立体异构体，溶剂合物，前药和药学上可接受的形式，其中变量在本文中定义。
-
公开(公告)号：US20230212158A1
公开(公告)日：2023-07-06
申请号：US17998261
申请日：2021-05-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Prasada Rao Jalagam , Susheel Jethanand Nara , Manoranjan Panda , Murugesan Natesan , Pratik Devasthale
IPC: C07D405/14 , C07D405/04 , C07D487/08
CPC classification number: C07D405/14 , C07D405/04 , C07D487/08
Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (Formula (I))
-
Patent Agency Ranking
公开(公告)号：US20190314346A1
公开(公告)日：2019-10-17
申请号：US16445913
申请日：2019-06-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: A61K31/438 , C07F9/59 , C07D401/10 , C07D401/14 , A61K31/5377 , C07D413/14 , C07D221/20 , C07D413/04 , A61K31/4439 , C07D401/04 , A61K31/4418 , C07D211/90 , A61K31/675 , C07D405/14 , C07F9/40 , C07F9/535 , C07D211/86 , C07D417/14 , C07D417/04 , C07D413/12 , C07D407/14 , C07D401/12 , A61K45/06
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US09974778B2
公开(公告)日：2018-05-22
申请号：US15316853
申请日：2015-06-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Pratik Devasthale , Fang Moore , James Mignone , Wei Wang
IPC: A61K31/4418 , C07D417/04 , C07D417/14 , C07D409/14 , C07D213/82 , C07D413/04 , A61K31/4439 , C07D401/04 , C07D213/80 , C07D409/04 , C07D401/12 , A61K31/444 , C07D401/14 , C07D413/12 , A61K45/06 , C07D213/74 , C07D405/04 , A61K31/4412
CPC classification number: A61K31/4418 , A61K31/4412 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D213/74 , C07D213/80 , C07D213/82 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/04 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/14
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US20180133198A1
公开(公告)日：2018-05-17
申请号：US15867825
申请日：2018-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: A61K31/438 , C07F9/59 , A61K31/4418 , C07F9/40 , C07D417/14 , C07D417/04 , C07D413/14 , C07D413/12 , C07D413/04 , C07D407/14 , C07D405/14 , C07D401/14 , C07D401/12 , C07D401/10 , C07D401/04 , C07D221/20 , C07D211/90 , C07D211/86 , A61K45/06 , A61K31/675 , A61K31/5377 , A61K31/4439 , C07F9/535
CPC classification number: A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D211/86 , C07D211/90 , C07D221/20 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07F9/4006 , C07F9/5352 , C07F9/59
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US20160031816A1
公开(公告)日：2016-02-04
申请号：US14883067
申请日：2015-10-14
Applicant: Bristol-Myers Squibb Company
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Dong Cheng , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: C07D211/90 , C07D221/20 , C07D401/10 , C07D401/04 , C07D405/14 , C07D401/14 , C07D211/86 , C07D417/04 , C07D413/12 , C07D401/12 , C07D413/04
CPC classification number: A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D211/86 , C07D211/90 , C07D221/20 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07F9/4006 , C07F9/5352 , C07F9/59
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US08791091B2
公开(公告)日：2014-07-29
申请号：US13688584
申请日：2012-11-29
Applicant: Bristol-Myers Squibb Company
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: A61K31/675 , A61K31/4418 , A61K45/06 , A61K31/438 , A61K31/4439 , A61K31/5377 , C07D401/04 , C07D413/04 , C07D413/14 , C07F9/59 , C07D401/14 , C07D211/90 , C07D221/20
CPC classification number: A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/5377 , A61K31/675 , A61K45/06 , C07D211/86 , C07D211/90 , C07D221/20 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/14 , C07F9/4006 , C07F9/5352 , C07F9/59
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的单酰基甘油酰基转移酶2型（MGAT2）抑制剂。
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.043 seconds)
